• IGI Laboratories Inc., of Buena, N.J., received approval from the FDA for its supplemental filing for the site transfer of econazole nitrate cream 1 percent to its manufacturing facility in Buena, N.J. The company purchased econazole nitrate cream 1 percent from Praxco LLC in February.

• Mylan Pharmaceuticals Inc., of Pittsburgh, has been sued by Teijin Ltd., of Osaka, Japan, and Teijin Pharma Ltd., of Tokyo, as well as Takeda Pharmaceuticals USA Inc., of Deerfield, Ill., part of Takeda Pharmaceutical Co. Ltd., in connection with the filing of an abbreviated new drug application (ANDA) with the FDA for febuxostat tablets, 40 mg and 80 mg. The product is the generic version of Mylan’s Uloric, which is indicated for the chronic management of hyperuricemia in patients with gout. Mylan contended it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for that product and expects to be eligible for 180 days of marketing exclusivity upon final FDA approval. The plaintiffs have filed a lawsuit against Mylan in the U.S. District Court for the District of Delaware.